MARKET

KDMN

KDMN

Kadmon Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.790
+0.130
+3.55%
After Hours: 3.700 -0.09 -2.37% 17:46 05/07 EDT
OPEN
3.700
PREV CLOSE
3.660
HIGH
3.835
LOW
3.630
VOLUME
977.85K
TURNOVER
--
52 WEEK HIGH
5.73
52 WEEK LOW
3.145
MARKET CAP
651.19M
P/E (TTM)
-5.6148
1D
5D
1M
3M
1Y
5Y
CECE, CCXI, CNDT and KDMN among after-hours movers
Gainers: [[CECE]] +4.3%. [[CCXI]] +4.2%. [[SVC]] +3.6%. [[GTX]] +3.0%. [[BBGI]] +3.0%.Losers: [[CNDT]] -2.9%. [[KDMN]] -2.4%. [[CHMA]] -2.0%. [[ISBC]] -2.0%. [[VBLT]] -1.9%.
Seekingalpha · 2d ago
10-Q: KADMON HOLDINGS, INC.
Edgar Online - (EDG = 10Q, 10K) · 3d ago
BRIEF-Kadmon Holdings Inc QTRLY Loss Per Share $ 0.17
reuters.com · 3d ago
Kadmon EPS beats by $0.01, misses on revenue
Kadmon (KDMN): Q1 GAAP EPS of -$0.17 beats by $0.01.Revenue of $0.56M (-91.7% Y/Y) misses by $0.13M.Press Release
Seekingalpha · 3d ago
Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021.
ACCESSWIRE · 3d ago
-- Earnings Flash (KDMN) KADMON HOLDINGS Posts Q1 Revenue $563,000
MT Newswires · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kadmon Holdings (KDMN), Lineage Cell Therapeutics (LCTX) and Ascendis Pharma (ASND)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kadmon Holdings (KDMN), Lineage Cell Therapeutics (LCTX) and Ascendis
SmarterAnalyst · 5d ago
Rosen, Global Investor Counsel, Encourages Kadmon Holdings, Inc. Investors with Losses to Secure Counsel Before Important Deadline - KDMN
New York, New York, Apr 30, 2021 (Newsfile Corp via COMTEX) -- New York, New York--(Newsfile Corp. - April 30, 2021) - WHY: Rosen Law Firm, a global investor...
Newsfile Corp · 05/01 00:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KDMN. Analyze the recent business situations of Kadmon Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KDMN stock price target is 12.17 with a high estimate of 20.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 199
Institutional Holdings: 167.84M
% Owned: 97.68%
Shares Outstanding: 171.82M
TypeInstitutionsShares
Increased
52
15.39M
New
31
6.57M
Decreased
40
21.01M
Sold Out
10
1.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman/Independent Director
Tasos Konidaris
President/Chief Executive Officer/Director
Harlan Waksal
Chief Financial Officer/Executive Vice President
Steven Meehan
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Gregory Moss
Executive Vice President
John Ryan
Senior Vice President
Simon Cooper
Independent Director
Eugene Bauer
Independent Director
David Cohen
Independent Director
Arthur Kirsch
Independent Director
Nancy Miller-Rich
Independent Director
Cynthia Schwalm
No Data
About KDMN
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.

Webull offers kinds of Kadmon Holdings Inc stock information, including NASDAQ:KDMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDMN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDMN stock methods without spending real money on the virtual paper trading platform.